Henoch-Schönlein purpura

Current Opinion in Rheumatology

Volumn 13, Issue 1, 2001, Pages 35-40

  Saulsbury, Frank T ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN RECEPTOR;

ANAPHYLACTOID PURPURA; ARTICLE; CHILDHOOD DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; GLYCOSYLATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

HUMANS; IMMUNOGLOBULIN A; PURPURA, SCHOENLEIN-HENOCH;

EID: 0035159906     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200101000-00006     Document Type: Article

References (64)

1. Anaphylactoid purpura in children (Schönlein-Henoch syndrome)
2. Henoch-Schönlein purpura in children: Report of 100 patients and review of the literature
3. Schönlein-Henoch nephritis
4. Schönlein-Henoch purpura in adult patients
5. The clinical spectrum of Henoch-Schönlein purpura in infants and young children
6. Henoch-Schönlein purpura in adulthood and children: Two different expressions of the same syndrome
7. Henoch-Schönlein purpura nephritis
8. Steroid effects on the course of abdominal pain in children with Henoch-Schönlein purpura
9. Henoch-Schönlein nephritis: Long-term prognosis of unselected patients
10. Long-term renal prognosis of Henoch-Schönlein purpura in an unselected childhood population
11. Long-term prognosis of Henoch-Schönlein nephritis in adults and children
12. Clinical outcome of Schönlein-Henoch purpura nephritis in children
13. Prognostic significance of the glomerular changes in Henoch-Schönlein nephritis
14. Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis
15. The effect of triple therapy on rapidly progressive type of Henoch-Schönlein nephritis
16. Response of crescentic Henoch-Schönlein purpura nephritis to corticosteroid and azathioprine therapy
17. Multiple combined therapy for severe Henoch-Schönlein nephritis in children
18. Effective therapy for severe Henoch-Schönlein purpura nephritis: A clinical and histopathologic study
19. Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schönlein purpura nephritis in children
20. The structure and function of human IgA
21. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus
22. Heavy and light chain composition of serum IgA and IgA rheumatoid factor in Henoch-Schönlein purpura
23. O-linked oligosaccharides from human serum immunoglobulin A1
24. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions
25. Analysis of IgA1 O-glycans in IgA nephropathy by fluoraphore-assisted carbohydrate electrophoresis
26. Structure of the O-glycosidically linked oligosaccharides of human IgD
27. Is Henoch-Schönlein purpura the systemic form of IgA nephropathy?
28. Progress in the pathogenesis of IgA nephropathy
29. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy
30. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy
31. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG
32. IgA1 glycosylation and the pathogenesis of IgA nephropathy
33. Binding capacity of serum IgA to jacalin in patients with IgA nephropathy using jacalin-coated microplates
34. Association of asialo-galactosyl β1-3 N-acetylgalactosamine on the hinge with a conformational instability of jacalin-reactive immunoglobulin A1 in immunoglobulin A nephropathy
35. Direct evidence for decreased sialylalion and galactosylatron of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy by mass spectrometry
36. Alterations in the O-linked glycosylation of IgA1 in children with Henoch-Schönlein purpura
37. Abnormal IgA glycosylation in Henoch-Schonlein purpura restricted to patients with clinical nephritis
38. Extracellular neuraminidase production of streptococci associated with acute nephritis
39. Neuraminidase activity and free sialic acid in the serum of patients with acute post-streptococcal glomerulonephritis
40. Hemolytic-uremic syndrome associated with Streptococcus pneumonias
41. The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines
42. Leucocyte β1,3 galactosyltransferase activity in IgA nephropathy
43. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies
44. All forms of human IgA antibodies bound to antigen interfere with complement (C3) fixation induced by IgG or by antigen alone
45. The role of the carbohydrate chains in the complement (C3) fixation by solid-phase bound human IgA
46. Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy
47. Pathogenesis of IgA nephropathy: In vitro activation of human mesangial cells by IgA immune complexes leads to cytokine secretion
48. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation
49. Receptors for immune-complexes activate gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: Role of TGF-beta
50. Interaction of IgA Fcα receptors of human mesangial cells activates transcription factor nuclear factor-κB and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10
51. Receptor-mediated binding and uptake of immunoglobulin A by human liver
52. Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Cα2 and Cα3 in human IgA1
53. Alterations in the IgA carbohydrate chains influence the cellular distribution of IgA1
54. Down regulation of Fcα receptors on blood cells of IgA nephropathy patients: Evidence for a negative regulatory role of serum IgA
55. Cellular distribution, regulation, and biochemical nature of an Fcα receptor
56. Evidence for a specific IgA receptor in rat and human mesangial cells
57. Mesangial cells possess on asialo-glycoprotein receptor with affinity for human immunoglobulin A
58. Proinflammatory cytokines regulate FcαR expression by human mesangial cells in vitro
59. Glomerular Fc alphaR expression and disease activity in IgA nephropathy
60. Expression and physical association of Fc alpha receptor and Fc receptor gamma chain in human mesangial cells
61. Human mesangial cells in culture and in kidney sections fail to express Fc alpha receptor (CD89)
62. Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells
63. Identification of a novel Fcα receptor expressed by human mesangial cells
64. Fcα receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease): Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice